佐力藥業(300181.SZ):浙醫健收到《經營者集中反壟斷審查不實施進一步審查決定書》
格隆匯5月7日丨佐力藥業(300181.SZ)公佈,2020年3月25日,公司控股股東、實際控制人俞有強與浙江省醫療健康集團有限公司(“浙醫健”)簽署了《股份轉讓協議》,俞有強將其持有公司的部分股份分次轉讓給浙醫健,其中第一次股份協議轉讓數量為4329.6821萬股,佔發行前公司總股本的7.11%;俞有強股票限售解除後進行第二次轉讓,股份數量為4799.6906萬股,佔發行前公司總股本的7.89%。同時,俞有強出具了《關於放棄浙江佐力藥業股份有限公司股份表決權的承諾函》,在俞有強首期將持有公司的4329.6821萬股股份轉讓給浙醫健,並且俞有強放棄全部表決權生效後及經浙醫健提名並當選的董事(非俞有強推薦的董事)占上市公司董事會半數以上席位,浙醫健即成為公司的控股股東,浙江省國資委將成為公司實際控制人。同日,公司與浙醫健簽署了附條件生效的《非公開發行股份認購協議》,擬向浙醫健非公開發行股票,募集資金總額不超過約2.72億元(含),募集資金淨額將用於償還銀行借款及補充流動資金。2020年3月27日,為了符合《深圳證券交易所上市公司股份協議轉讓業務辦理指引》及其他相關規定的要求,俞有強與浙醫健簽署了《股份轉讓協議》補充協議。
近日,浙醫健收到國家市場監督管理總局出具的《經營者集中反壟斷審查不實施進一步審查決定書》(反壟斷審查決定〔2020〕176號),具體內容如下:
“根據《中華人民共和國反壟斷法》第二十五條規定,經初步審查,現決定,對浙江省醫療健康集團有限公司收購浙江佐力藥業股份有限公司股權案不實施進一步審查。你公司從即日起可以實施集中。
該案涉及經營者集中反壟斷審查之外的其他事項,依據相關法律辦理。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.